NeOnc's Brain Cancer Drug Beats Survival Benchmarks and the CEO Is Buying — But Can a Five-Person Company With Months of Cash Turn Promise Into Product?

Shares of NeOnc Technologies Holdings (NTHI) surged +10.8% to $5.44 on August 18, extending a rally that has nearly doubled the stock from its $3.01 52-week low, even as broader markets fell under pressure from rising yields. The catalyst: an experimental nasal spray for recurrent brain cancer that is posting survival numbers Wall Street did not expect — and a CEO spending his own money to signal he believes them.

• A Small Trial Produced a Big Survival Signal. NeOnc's Phase 2a study of intranasal NEO100 for recurrent brain cancer achieved a six-month progression-free survival rate of 48.9%, significantly surpassing the 20% benchmark set for standard care.

Median overall survival reached 26.09 months, with a high percentage of patients alive at various intervals post-treatment. For context, current salvage therapies for recurrent brain cancer typically yield six to nine months of survival. That gap — if it holds up — points to a genuinely differentiated treatment. However, confirmation through a randomized study remains necessary.

• The CEO Put His Own Cash Behind the Data. On August 14, CEO Amir Heshmatpour acquired 12,000 shares at an average of $3.79, then on August 17 bought another 3,000 shares at roughly $4.37 — totaling approximately $58,600 across the two transactions. These are open-market buys with personal funds, not option grants. Over the past year, Heshmatpour has invested nearly $1 million in open-market purchases. When a CEO accelerates buying after a data readout, it tells investors he sees value the market hasn't priced.

• The Cash Problem Hasn't Gone Away. NeOnc had just $138,601 in cash at March 31, 2026, plus a $10 million undrawn credit line expected to fund operations only into September 2026.

With roughly 26 million shares outstanding and only five employees, this is a micro-cap that will almost certainly need to raise money before any larger trial begins. That dilution risk is the single biggest reason the stock trades at $5.44 despite analyst price targets averaging $16 and reaching as high as $20.

• The FDA Meeting Will Decide What Comes Next. NeOnc intends to request a Type B meeting with the FDA to align on a registrational development path — essentially asking regulators what kind of larger trial would be needed for potential drug approval. That conversation will determine the cost, timeline, and ultimate probability of NEO100 reaching patients. Until it happens, the stock trades on hope and a 24-patient study.